


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6594515/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors. PLoS Computational Biology, 2009, 5, e1000387.	3.2	232
2	Drugs for the Treatment of Zika Virus Infection. Journal of Medicinal Chemistry, 2020, 63, 470-489.	6.4	63
3	Marinopyrrole Derivatives as Potential Antibiotic Agents against Methicillin-Resistant Staphylococcus aureus (II). Marine Drugs, 2013, 11, 2927-2948.	4.6	24
4	Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors. European Journal of Medicinal Chemistry, 2015, 90, 315-331.	5.5	23
5	Development and Validation of a Phenotypic High-Content Imaging Assay for Assessing the Antiviral Activity of Small-Molecule Inhibitors Targeting Zika Virus. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	22
6	Novel fluorinated pyrrolomycins as potent anti-staphylococcal biofilmÂagents: Design, synthesis, pharmacokinetics and antibacterialÂactivities. European Journal of Medicinal Chemistry, 2016, 124, 129-137.	5.5	20
7	Marinopyrrole Derivatives as Potential Antibiotic Agents against Methicillin-Resistant Staphylococcus aureus (III). Marine Drugs, 2014, 12, 2458-2470.	4.6	19
8	Cyclic Marinopyrrole Derivatives as Disruptors of Mcl-1 and Bcl-xL Binding to Bim. Marine Drugs, 2014, 12, 1335-1348.	4.6	14
9	Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib. Pharmaceutics, 2020, 12, 330.	4.5	12
10	Marinopyrrole Derivatives with Sulfide Spacers as Selective Disruptors of Mcl-1 Binding to Pro-Apoptotic Protein Bim. Marine Drugs, 2014, 12, 4311-4325.	4.6	9
11	Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus. BMC Cancer, 2019, 19, 837.	2.6	8
12	Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. Clinical Pharmacology and Therapeutics, 2021, 109, 184-192.	4.7	6
13	Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations. Oncology and Therapy, 2021, 9, 525-539.	2.6	6
14	The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants. Clinical Pharmacokinetics, 2021, 60, 1303-1312.	3.5	5